Our transactions group works closely with a multi-disciplinary team of lawyers focusing on representing clients in the life sciences industry. This team includes professionals in the following practice areas: Life Sciences Transactions, Antitrust, Patent Litigation, Product Liability, Trademarks, False Advertising and Consumer Fraud and White Collar Litigation and Internal Investigations.
Because of our wealth of experience representing life sciences companies, clients routinely look to us to advise not only on legal issues, but also on industry norms and “market” terms. Additionally, our team of scientific advisers hold advanced degrees in molecular biology, chemistry, biochemistry and medicine, among other fields. They work alongside our lawyers to provide guidance and understanding of the science behind the business.
Mergers and Acquisitions
M&A activity involving pharmaceutical and biotechnology companies has dramatically increased during the past few years and continues unabated. Industry dynamics, such as blockbuster drugs coming off patent and the desire of pharmaceutical companies to bolster their pipelines and reduce costs, are likely to drive continued consolidation.
Kaye Scholer Life Sciences M&A lawyers represent buyers and sellers on mergers, acquisitions and other business combinations. Our industry experience can be particularly helpful in deal structuring and due diligence, as we are highly attuned to the business and regulatory environment in which our clients operate. We bring not only an experienced team of M&A lawyers to the deal, but also the knowledge and experience on issues that most directly affect life sciences companies such as intellectual property, commercial relationships, regulatory matters and industry dynamics.
We are also one of the leading firms in Exon Florio/CFIUS/national security matters, which is becoming of increasing importance in Life Sciences transactions.
Licenses and Collaborations
Kaye Scholer Life Sciences lawyers advise and negotiate licensing, collaboration and other commercial arrangements throughout a product’s life cycle, from the pre-clinical research stage through clinical development and, following approval, commercialization.
- Research collaborations and license agreements
- University licenses and sponsored research agreements
- Option agreements
- Pre-clinical research agreements
- Material transfer agreements (MTA’s)
- Licenses and co-development collaborations
- Clinical research agreements
- Contract research organization (CRO) agreements
- Co-promotion/co-development alliances
- Marketing and distribution agreements
- Product acquisitions and divestitures
- Manufacturing and supply agreements
- Contract sales organization (CSO) agreements
Kaye Scholer’s life science financing lawyers have an in-depth understanding of the financing needs of life science companies and the opportunities that arise for issuers and investors in today’s challenging financing environment. We advise both life science companies and their investors on a full range of financing matters including venture capital financing for early stage companies, initial public offerings and PIPE (private investment in public entity) transactions for public companies. Our investor clients include private equity funds, venture capital funds and mature life sciences companies investing in early stage companies. We are experienced in financing transactions that involve control and minority investments, “club deals” and co-investments, all stages of the investment cycle and greatly varied transaction structures.